TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06189157: An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE

Sponsor: Miltenyi Biomedicine GmbH · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 29 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,073,225

Rescue Site Savings

+$3,343,050

Unlock Full NCT06189157 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06189157 Rescue Dossier →